Atea Pharmaceuticals Inc Stock

$2.90

3.20% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US04683R1068

Symbol

AVIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Atea Pharmaceuticals Inc Stock price

$2.90

-27.44 90.44% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.09 3.20%

ISIN

US04683R1068

Symbol

AVIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$248.18m
Enterprise Value	$-175.81m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	1.39
P/B ratio (TTM) P/B ratio	0.60
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-162.19m
Free Cash Flow (TTM) Free Cash Flow	$-126.20m
Cash position	$425.44m
EPS (TTM) EPS	$-1.65
P/E forward	negative
Short interest	4.47%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Atea Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Atea Pharmaceuticals Inc forecast:

1x Buy

33%

1x Hold

33%

1x Sell

33%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Atea Pharmaceuticals Inc forecast:

Buy

33%

Hold

33%

Sell

33%

Analyst Estimates with Stock Price Targets

Financial data from Atea Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	0.42 0.42	0% 0% -
Gross Profit	-0.42 -0.42	0% 0% -
- Selling and Administrative Expenses	45 45	7% 7% -
- Research and Development Expense	116 116	19% 19% -
EBITDA	-162 -162	16% 16% -
- Depreciation and Amortization	0.42 0.42	0% 0% -
EBIT (Operating Income) EBIT	-162 -162	16% 16% -
Net Profit	-139 -139	15% 15% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Atea Pharmaceuticals Inc Stock News

Neutral

GlobeNewsWire

●

8 days ago

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Sup porting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14 , 2...

Neutral

GlobeNewsWire

●

14 days ago

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Needed in Phase 1 Stu...

Neutral

GlobeNewsWire

●

20 days ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Panel to Discuss Current Challenges Encountered by Patients with HCV , Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call; Quarterly Calls to Resume with Second Quarter 2025 Financial Results BOSTON, May 01, 2025 (GLOBE ...

More Atea Pharmaceuticals Inc News

Company Profile

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Head office	United States
CEO	Jean-Pierre Sommadossi
Employees	56
Founded	2012
Website	www.ateapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now